Antibiotics/pharmacology Flashcards
11687 – The skin is an unsatisfactory environment for many microbes because of its
1: resident microbial flora
2: alkaline pH
3: dryness
4: mucus secretions
TFTF
The skin is normally dry (ie unsuitable for microbial growth) with an acid pH (around 5.5 in places such as the forehead), and in most areas contains a resident microflora of bacteria (eg staphylococci, coryneforms, anaerobes such as Propionibacterium and lipophilic yeasts (eg Malassezia furfur). Most normal flora microbes occur in areas high in humidity and secretions (eg scalp, foot, axilla). None of the secretions (eg sweat, sebaceous) contains mucus; with the presence of fatty acids, lactate, salt (NaCl), and products of keratinisation in secretions
contributing to the ‘acid mantle’ that covers most skin areas. The skin of the feet while moist (sweat) is not covered in oily secretions; hence its ability to harbour Gram-negative bacilli such as Acinetobacter and pseudomonads. All of these properties (dryness of some areas, acidity, resident flora occupying available niches) renders the skin unsuitable as an environment for many microbes. Those that occur as part of the normal flora are adapted in some way to these conditions.
25994 – In relation to antibiotics
1: quinolones are well absorbed after oral administration
2: aminoglycosides include vancomycin
3: cephalosporins may induce bleeding problems following some prolonged administration
4: cephalosporins are generally less resistant than the penicillins to staphylococcal beta-lactamases
TFTF
C.S.S. 2nd ed. P.155/156 Update (antibiotics) M14-M20
A feature of the quinolone group of antimicrobials is their good bioavailability and excellent body distribution after oral administration. Newer quinolones also have long half-lifes permitting once daily oral dosing in most cases. The aminoglycosides now commonly used are gentamicin, tobramycin, netilmicin, and amikacin; vancomycin is a cell wall active glycopeptide unrelated to the ribosomalactive aminoglycosides. One of the major problems of prolonged cephalosporin use is a reduction in the body’s vitamin K levels (vitamin K is synthesised by gut microbes) with consequent platelet dysfunction and bleeding (hypoprothrombinaemia). This is particularly a feature of cephalosporins possessing a methyl-thiotetrazole side chain (eg cefamandole, cefotetan), and although uncommon, has been seen in the elderly and/or malnourished surgical patient. It can be treated and/or prevented by vitamin K supplementation. MRSA are resistant to all Β-lactams (including flucloxacillin, coamoxyclav, piperacillin/tazobactam, imipenem) because resistance is associated with a new target site (penicillin binding protein 2a) to which all Β-lactams have low affinity, and not to penicillinase (Β-lactamase) production. However, all of the penicillins listed above are penicillinase-stable and effective against ‘normal’ (methicillin-susceptible) strains of Staphylococcus aureus.
11728 – In relation to antibiotics
1: quinolones are well absorbed after oral administration
2: aminoglycosides include vancomycin
3: some cephalosporins may induce bleeding problems following prolonged administration
4: piperacillin/tazobactam is effective therapeutically against MRSA
TFTF
A feature of the quinolone group of antimicrobials is their good bioavailability and excellent body distribution after oral administration. Newer quinolones also have long half-lifes permitting once daily oral dosing in most cases. The aminoglycosides now commonly used are gentamicin, tobramycin, netilmicin, and amikacin; vancomycin is a cell wall active glycopeptide unrelated to the ribosomalactive aminoglycosides. One of the major problems of prolonged cephalosporin use is a reduction in the body’s vitamin K levels (vitamin K is synthesised by gut microbes) with consequent platelet dysfunction and bleeding (hypoprothrombinaemia). This is particularly a feature of cephalosporins possessing a methyl-thiotetrazole side chain (eg cefamandole, cefotetan), and although uncommon, has been seen in the elderly and/or malnourished surgical patient. It can be treated and/or prevented by vitamin K supplementation. MRSA are resistant to all Β-lactams (including flucloxacillin, coamoxyclav, piperacillin/tazobactam, imipenem) because resistance is associated with a new target site (penicillin binding protein 2a) to which all Β-lactams have low affinity, and not to penicillinase (Β-lactamase) production. However, all of the penicillins listed above are penicillinase-stable and effective against ‘normal’ (methicillin-susceptible) strains of Staphylococcus aureus.
23784 – In relation to antibiotics
1: vancomycin is active only against Gram positive bacteria
2: alcohol intolerance is an adverse reaction seen with metronidazole
3: tetracyclines should not be used in young children
4: gentamicin is not active against obligate anaerobes
TTTT
Update (antibiotics) pM12-M22
23059 – In relation to antibiotics
1: fusidic acid is a useful consideration for infections by Staphylococcus aureus
2: rifampicin is well absorbed from the alimentary tract
3: chloramphenicol penetrates better than most other antibiotics into the CSF
4: vancomycin is well absorbed after oral administration
TTTF
Update (antibiotics) pM18-M21
9795 – Examples of cell wall active antibacterials include
1: vancomycin
2: imipenem
3: piperacillin
4: gentamicin
TTTF
Toouli et al, Integrated Basic Surgical Sciences, Ch 37.2
10378, 23299 – Antibiotics which can be used effectively in the empiric therapy of intra-abdominal sepsis originating from the pancreas include
1: imipenem alone
2: gentamicin alone
3: a combination of piperacillin and tazobactam (Tazocin)
4: cefotaxime alone
TFTF
Smith & Payne Aust. NZJ Surgery ‘94.
However, in this case upper gastrointestinal surgery raises the distinct possibility of the participation of enterococci, and possibly yeasts. Although it is generally agreed that empiric cover against yeasts is not at present warranted, certainly the potential for yeasts to be involved should be considered, and
requested in specimen cultures. Imipenem-type drugs, and piperacillin/tazobactam have proved to be superior to most antimicrobials in this situation apparently covering all important aerobic (eg Gram-negative bacilli, staphylococci, streptococci) and obligate anearobes (eg Bacteriodes fragilis, clostridia). Where patients fail to respond as anticipated to one of these drugs, the participation of yeasts such as Candida albicans should be seriously considered. Aminoglycosides such as gentamicin, or third generation cephalosporins like cefotaxine fail to cover obligate anaerobes and bacteria such as Enterococcus faecalis.
22609 – Antibiotics/combinations which are adequate prophylaxis for biliary surgery include
1: Augmentin (co-amoxyclav)
2: penicillin
3: amoxycillin plus gentamicin
4: flucloxacillin plus metronidazole
TFTF
Antibiotic Update: Page: AM27.
23309 – The following are therapeutically useful microbe/antimicrobial agent combinations in the surgical patient
1: candida albicans/fluconazole
2: bacteroides fragilis/amoxycillin
3: staphylococcus aureus/benzyl penicillin
4: enterococcus faecalis/metronidazole
TFFF
Smith & Payne Aust. NZJ Surgery ‘94
15568 – The following are therapeutically useful microbe/drug combinations
1: methicillin-resistant Staphylococcus aureus/imipenem
2: Bacteroides fragilis/benzyl penicillin
3: Clostridium difficile/metronidazole
4: Escherichia coli/gentamicin
FFTT
Refer to Aust NZJ Surgery, 1994; STEM Module: Surgical Infections and Antimicrobials.
10393, 23694 – Therapeutically useful microbe/antimicrobial agent combinations include
1: Bacteroides fragilis/metronidazole
2: Staphylococcus aureus/piperacillin
3: Enterococcus faecalis/gentamicin
4: Mycoplasma pneumoniae/imipenem
TFFF
Smith & Payne Aust. N.Z. Journal Surgery ‘94.
Bacteroides fragilis has remained universally
susceptible to metronidazole and imipenem or meropenem (and also chloramphenicol). Increasing resistance to clindamycin and cefoxitin is common, while the likes of piperacillin/tazobactam and coamoxyclav are still acceptable second line alternatives to metronidazole or the glycopeptides (eg imipenem). Over 80% of Staphylococcus aureus strains now elaborate penicillinases, which destroy the activity of most penicillins (eg penicillin G, amoxycillin, piperacillin, ticarcillin) other than the so-called penicillinase-stable group eg flucloxacillin, dicloxacillin. Addition of a beta-lactamase inhibitor (eg clavulanic acid, tazobactam, sulbactam) restores the activity of penicillinase-labile penicillins (eg amoxycillin, piperacillin) against S. aureus (eg amoxycillin plus clavulanic acid or co-amoxyclav). Enterococci reveal inherent decreased susceptibility or resistance to aminoglycosides and penicillin G. However, combinations of gentamicin plus penicillin reveal synergy against enterococci and this combination is a useful therapeutic consideration. Ampicillin (or amoxycillin) is more active naturally than penicillin G against enterococci this also reveals increased activity when combined with gentamicin. The usual therapy for enterococcal infections is ampicillin plus gentamicin. Piperacillin is somewhat similar to ampicillin. In addition some of the newer quinolones, eg clinafloxacin, show useful activity against enterococci. Mycoplasmas do not possess a cell wall, and are unaffected by cell wall active antimicrobials such as beta-lactams and vancomycin. Imipenem is a beta-lactam. The usual therapeutic option for infections involving mycoplasmas is a macrolide (eg erythromycin,
clarithromycin).
23909 – Aminoglycosides
1: are well absorbed after oral administration
2: are synergistic with penicillins
3: have a high therapeutic index
4: are ineffective against Staphylococcus auerus
FTFF
C.S.S. PAGE: 155, 159 Update pM16
3: narrow therapeutic index - high risk of toxicity
11718 – Aminoglycosides
1: have activity against Gram-negative bacilli
2: reveal synergy with penicillins
3: tend to accumulate in renal tissues
4: are well absorbed after oral administration
TTTF
Aminoglycosides are generally safe drugs with known adverse effects, which can be administered by intravenous or intramuscular push or infusion over 15-20 minutes, and which show excellent activity against many Gram-negative bacilli. They also have often unappreciated anti-Staphylococcus aureus activity (including some MRSA), but are devoid of therapeutic anti-anaerobe activity. Although ineffective by themselves against enterococci and streptococci, they reveal synergy with penicillins against these two groups of bacteria. Older regimens of 8-12 hourly dosing, have in many cases been replaced by 24 hourly schedules. This is because aminoglycosides display concentration-dependent bacterial killing (unlike the Β-lactams), and a pronounced post-antibiotic effect (PAE) against many bacteria. In addition, complete ‘wash out’ of the previous dose before administering the next dose results in enhanced cidal activity of the second dose (bacteria exhibit what has been termed adaptive resistance in the presence of low levels of the drug), while once a day dosing is clearly less toxic (to kidney and ear) than multiple daily doses. The most feared complications of aminoglycoside use are nephrotoxicity and ototoxicity. These both result from excessive local accumulation of drug in the presence of poor or deteriorating renal function. Monitoring of trough levels is essential in all patients receiving more than a couple of days of aminoglycoside therapy, especially in the elderly or where renal function is deteriorating. Renal toxicity is reversible, although ototoxicity is not. Some evidence is available that susceptibility to ototoxicity is related to a defect (mutation) in a mitochondrial gene. Aminoglycosides are not absorbed from the alimentary tract, and cannot be given orally if systemic distribution is required.
15182 – Gentamicin
1: reveals concentration dependant bacterial killing
2: can be used successfully once daily in many surgical situations
3: is effective against the gram-negative Bacteroides fragilis
4: cannot be administered by intramuscular injection
TTFF
Refer to updates of Aust. NZ Journal of Surgery
3: gent not effective against anaerobes - metronidazole works!
11713 – Cephalosporins
1: are active therapeutically against enterococci
2: are associated with greater allergic problems than penicillins
3: have no action against Staphylococcus aureus
4: are generally more resistant to beta-lactamases than the penicillins
FFFT
Cephalosporins can be divided into four generations - reflecting to some extent their date of discovery and increasing spectrum of activity against Gram-negative bacteria (from first to third generation). While activity against some Gram-positive cocci (eg Staphylococcus aureus) decreases slightly from first to third generation, the latter generations, including fourth, have excellent activity against most
streptococci. Second generation compounds, such as cefuroxime, are excellent anti-S. aureus drugs. Most cephalosporins are parenteral-only drugs, although oral formulations are gradually being produced. All cephalosporins show no therapeutic activity against enterococci. Indeed, the widespread use of cephalosporins for prophylaxis, and in some countries (eg USA) for therapy, is thought to be one of the main reasons enterococci have emerged as increasingly significant hospital pathogens. Apart from a few cephamycins (7-methoxycephalosporins) often referred to as second generation cephalosporins (eg cefoxitin, cefotetan), none of the cephalosporins has useful therapeutic activity against obligate anaerobes. Resistance to the likes of cefoxitin (the most active agent) is also now increasing in important anaerobes such as Bacteroides fragilis; cefoxitin and cefotetan are really
only second-line anti-anaerobe agents, although they have found a role in large bowel prophylaxis. Compared to penicillins, cephalosporins have always been significantly more resistant to Β-lactamase inactivation (eg first and second generation compounds have excellent activity against Staphylococcus aureus), and clearly are less likely to induce allergic/hypersensitive states. Cephalosporins can be used with reasonable safety in patients with mild allergy (eg skin rash) to penicillins, although should be avoided where anaphylaxis or similar serious event is likely. The degree of cross reactivity of cephalosporins in patients with penicillin allergy is around 10% or less.
23564 – The broad spectrum antibiotic amoxicillin
1: is effective in prevention of Clostridium difficile diarrhoea
2: is resistant to staphylococcal penicillinases
3: is cell wall active
4: is effective in meningitis
FFTF
C.S.S. 2nd ed. Page: 154-155 Update (antibiotic) M12-14
11708, 25986 – Augmentin (co-amoxiclav)
1: is a useful oral anti-staphylococcal agent
2: is effective against mycoplasma
3: has anaerobe activity
4: is not stable to penicillinase
TFTF
Coamoxyclav (‘Augmentin’ - although the generic name is now out of patent and may change eg ‘Synermox’, ‘Alpha-amoxyclav’), is a combination of two Β-lactams, amoxycillin and clavulanic acid. The latter is highly resistant to the activity of some Β-lactamases (eg staphylococcal penicillinases) and has high affinity for them. When administered together with the Β-lactamase labile amoxycillin, any Β-lactamase elaborated by the bacterial pathogen is attracted (and bound) to the clavulanic acid
leaving the amoxycillin ‘free’ to carry out its antibacterial activity. The activity of coamoxyclav relies on the two components (which are not physically bound) having similar body distribution and other pharmacokinetic properties. Coamoxyclav is available as an oral (as well as parenteral) formulation, although the clavulanate portion often has unpleasant gastrointestinal activity eg nausea, diarrhoea.
This cell wall active B-lactam combination is ineffective against mycoplasmas which do not possess a cell wall, but has excellent activity against many significant anaerobes including clostridia and Bacteroides fragilis, and against Staphylococcus aureus - the latter two bacteria elaborate Blactamase susceptible to inactivation by clavulanic acid.
Update - Microbiology Basic Principles PAGE:p M14
19432 – The antimicrobial of choice for sepsis involving Bacteroides fragilis is
A. penicillin G
B. clindamycin
C. metronidazole
D. cefoxitin
E. coamoxyclav (Augmentin)
C
As with most other obligate anaerobes, the most useful and potent therapeutic agent is metronidazole.
11723, 22058 – Antibiotics effective against Bacteroides fragilis include
1: penicillin G
2: coamoxyclav (Augmentin)
3: metronidazole
4: gentamicin
FTTF
C.S.S. 2ND ED. CHAPTER: 8 PAGE: 154-159 165.
Bacteroides fragilis is an encapsulated Gram-negative obligate anaerobe, frequently associated with intra-abdominal sepsis. It produces Blactamases capable of inactivating most penicillins (eg penicillin G, amoxycillin), but susceptible to clavulanic acid inactivation. Clavulanic acid thus renders coamoxyclav (amoxycillin plus clavulanic acid) a useful agent against B. fragilis. Aminoglycosides (eg gentamicin) have no predictable therapeutic activity against any obligate anaerobes including B. fragilis. As with most other obligate anaerobes, the most useful and potent therapeutic agent is metronidazole.
23874 – Antibiotics effective therapeutically against Bacteroides fragilis include
1: penicillin (benzyl penicillin)
2: coamoxyclav (Augmentin)
3: ceftriaxone
4: imipenem
FTFT
Aust. NZJ Surgery
23054 – Penicillins resistant to penicillinases (beta-lactamases) of Staphylococcus aureus include
1: penicillin V (phenoxy methyl penicillin)
2: amoxycillin
3: piperacillin
4: flucloxacillin
FFFT
C.S.S. 2ND. ED. PAGE: 155 Update pM14
14818 – Resistance in Staphylococcus aureus to β-lactam antibiotics may be mediated by
1: changes in the penicillin binding proteins
2: decreased permeability of the cell wall outer membrane
3: enzymatic destruction of the drug
4: mutation in the gyrase A gene
TFTF
Refer to Microbiology Update, Aust & NZ Journal Surgery 1994
11738 – Regarding the treatment of infections by methicillin-resistant Staphylococcus aureus
1: vancomycin is the only reliable empiric therapy
2: coamoxyclav is useful for some strains
3: imipenem is useful for some strains
4: an antibiotic such as fusidic acid maybe useful for some strains
TFFT
Methicillin-resistant Staphylococcus aureus (MRSA) elaborate a new penicillin-binding protein (PBP), PBP2a, which has low affinity for all B-lactam drugs, and permits growth of cells in the presence of Blactams. MRSA strains are resistant to all B-lactams (eg penicillin, flucloxacillin, coamoxyclav, cefuroxime, and imipenem), because of this new target PBP. Since the late 1950s, most (around 80% plus) strains of S. aureus have been resistant to many penicillins (eg benzylpenicillin, amoxicillin, piperacillin) because of the production of penicillinases (B-lactamases) which destroy the biological activity of the drug. Penicillinase-stable penicillins (eg flucloxacillin, coamoxyclav) must be used for the empiric treatment of S. aureus infections. MRSA strains, which only became common around the early 1990s, are resistant to these classical antistaphylococcal (ie penicillinase-stable) penicillins. The only antibiotic to which 100% of MRSA strains are consistently susceptible is vancomycin; although MRSA strains with reduced susceptibility to vancomycin are slowly appearing world-wide. In countries such as New Zealand and Australia, MRSA strains are community (cMRSA) as well as hospital based. While most hospital MRSA strains are multiresistant - ie also resistant to a variety of non Blactam antistaphylococcal agents - most cMRSA are not, and are susceptible to agents such as cotrimoxazole, fusidic acid, rifampicin, gentamicin and ciprofloxacin. Treatment of cMRSA infections usually relies on a combination of two of these drugs.
19707 – In a hospital where methicillin-resistant Staphylococcus aureus (MRSA) is absent, the empiric therapy for septicaemia involving
Staphylococcus aureus should be
A. Augmentin (co-amoxyclav)
B. ciprofloxacin
C. metronidadole
D. flucloxacillin
E. vancomycin
D
Aust. NZJ Surgery; Update
11753 – In hospitals where MRSA are absent, acceptable antibiotics for hip replacement surgery prophylaxis include
1: cephazolin alone
2: vancomycin alone
3: metronidazole plus amoxycillin
4: penicillin G plus flucloxacillin
TFFF
Hip replacement surgery, like open-heart surgery, is an area of ‘clean surgery’ where antimicrobial prophylaxis is clearly warranted and cost effective. The major potential pathogens to be covered are staphylococci - both Staphylococcus aureus and coagulase-negative species such as Staphylococcus epidermidis which have the ability to form biofilms and adhere to foreign materials eg screws, prostheses. First or second generation cephalosporins have ideal antibacterial spectra for this situation - cefamandole possibly has better overall antistaphylococcal activity than cephazolin, although the latter has a longer half life and better bone penetration and is favoured by many institutions. Vancomycin should not be used unless MRSA are a major consideration, and even then it is apparent that the glycopeptide teicoplanin is a better alternative (easier to administer, less potential toxicity and adverse reactions). In general, glycopeptides such as vancomycin and teicoplanin should be reserved for situations where no other antibiotic choice is available. Metronidazole plus amoxicillin is devoid of staphylococcal activity (metronidazole is effective only against obligate anaerobes, and amoxycillin against the likes of streptococci but not staphylococci which elaborate penicillinases). Penicillin G has minimal activity against S. aureus (less than 10% strains), and while flucloxacillin is active against methicillin-susceptible S. aureus, it has poor activity against many (around 50%) strains of coagulase-negative staphylococci. This combination (penicillin + flucloxacillin) is not adequate prophylaxis for hip replacement surgery.
8727 – Antibiotics effective therapeutically against methicillin susceptible Staphylococcus aureus include
1: cephalexin
2: coamoxyclav (Augmentin)
3: flucloxacillin
4: cefuroxime
TTTT
Smith, Payne, Berne, Surgeon’s Guide to Antimicrobial Chemotherapy, Ch 1; Smith & Payne, Integrated Basic Surgical Sciences, Ch 37.2
24329 – Features of vancomycin include
1: therapeutically active against methicillin resistant staphylococci, e.g. MRSA
2: no therapeutic activity against the obligate anaerobe Clostridium perfringens
3: no therapeutic activity against gram-negative bacilli
4: inhibits cell wall synthesis in susceptible bacteria
TFTT
Antibiotic Update Aust. NZJ Surgery Paper IBSS, Ch 37.2, p782-793 Module: Surgical Infections
11733 – Antifungals therapeutically useful for Candida fungaemia in the post surgery patient include
1: amphotericin B
2: griseofulvin
3: fluconazole
4: nystatin
TFTF
Antifungals target some part of the fungal cell absent or sufficiently different to the similar structure found in mammalian cells. As fungal and human cells are both eukaryotic in structure, finding antifungals which are sufficiently toxic for fungi without unduly harming the human cell is not easy. One obvious target is the fungal cell wall - a structure composed of various polysaccharides (eg chitin, cellulose, glucans) of which the glucans appear to provide the structural backbone akin to the peptidoglycan of bacterial cell walls. A few cell wall active antifungals have been developed (eg echinocandins, pneumocandins), and while appearing extremely promising in the laboratory (in vitro) have in general failed to be acceptable in clinical trials because of toxicity problems. Other potential targets are the ribosomes (eg elongation factor 2 which occurs in yeasts and not human cells), DNA/RNA synthesis or function, and the cell membrane. Flucytosine (5-fluorocytosine) and griseofulvin have as their target nucleic acids; these agents have found some clinical use (eg 5FC for yeast infections, griseofulvin for ringworm), but because they have some effects on human nucleic acids, are unsuitable where rapid cell growth and division is found (eg pregnancy). Most of the antifungals currently in clinical use are membrane-active compounds, inhibiting in some way the production of the sterol ergosterol in the cell membrane. Specificity for fungal rather than mammalian cells resides in the fact that ergosterol is a major component of fungal but not human cell membranes, (cholesterol is the major sterol found in mammalian cell membranes). The azole group of antifungals (eg fluconazole) inhibit the cytochrome P450 activity of an enzyme in the ergosterol pathway, while the polyenes (eg amphotericin B) inhibit in some way the amount of ergosterol in the membrane.
Cells lacking in sufficient ergosterol in the membrane ‘leak’ and die. Unfortunately amphotericin B does have some effects on the membranes of human cells, and has a well-documented toxicity profile. Azoles may interact with other drugs (eg cyclosporin) where the conserved cytochrome P450 is also significant in some way. Fluconazole and amphotericin are suitable for treating yeast (eg Candida) infections in surgical patients. In most cases, oral fluconazole (rather than intravenous amphotericin B) is the agent of choice, with amphotericin B being reserved for situation where WBC numbers or function is impaired (eg neutropenia). Fluconazole is much easier to administer and far less toxic than amphotericin B. Nystatin (a polyene) is presently only available as a cream/ointment for topical use, or as lozenges or ovules for lesions involving the mouth or vagina. It is not absorbed
from the gut following oral administration. Griseofulvin is only active against the dermatophytes (ringworm fungi).
24259 – Characteristics of the anti-fungal agent, fluconazole include
1: can be administered intravenously
2: has potential interaction with cytochrome P450 metabolised drugs
3: is a useful agent against Candida albicans
4: is less nephrotoxic than amphotericin B
TTTT
Aust. NZJ Surgery.